FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:560-569 August 10, 2006 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by O'Shaughnessy, J. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Gene-expression–profiling studies of primary breast tumors performed by different laboratories have resulted in the identification of a number of distinct prognostic profiles, or gene sets, with little overlap in terms of gene identity.

Methods To compare the predictions derived from these gene sets for individual samples, we obtained a single data set of 295 samples and applied five gene-expression–based models: intrinsic subtypes, 70-gene profile, wound response, recurrence score, and the two-gene ratio (for patients who had been treated with tamoxifen).

Results We found that most models had high rates of concordance in their outcome predictions for the individual samples. In particular, almost all tumors identified as having an intrinsic subtype of basal-like, HER2-positive and estrogen-receptor–negative, or luminal B (associated with a poor prognosis) were also classified as having a poor 70-gene profile, activated wound response, and high recurrence score. The 70-gene and recurrence-score models, which are beginning to be used in the clinical setting, showed 77 to 81 percent agreement in outcome classification.

Conclusions Even though different gene sets were used for prognostication in patients with breast cancer, four of the five tested showed significant agreement in the outcome predictions for individual patients and are probably tracking a common set of biologic phenotypes.

Source Information

From the Departments of Genetics (C.F., D.S.O., C.M.P.), Statistics and Operations Research (A.B.N.), and Pathology and Laboratory Medicine (C.M.P.), University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, Chapel Hill; and the Divisions of Diagnostic Oncology (L.W., B.W., L.J.V.) and Radiotherapy (D.S.A.N.), the Netherlands Cancer Institute, Amsterdam.

Drs. Fan and Oh contributed equally to this article.

Address reprint requests to Dr. Perou at Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7295, Chapel Hill, NC 27599, or at cperou{at}med.unc.edu.

Full Text of this Article

Related Letters:

Gene-Expression–Based Predictors for Breast Cancer
Goetz M. P., Ingle J. N., Couch F. J., Fan C., van't Veer L. J., Perou C. M.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:752-753, Feb 15, 2007. Correspondence

This article has been cited by other articles:

• Bhojwani, D., Kang, H., Menezes, R. X., Yang, W., Sather, H., Moskowitz, N. P., Min, D.-J., Potter, J. W., Harvey, R., Hunger, S. P., Seibel, N., Raetz, E. A., Pieters, R., Horstmann, M. A., Relling, M. V., den Boer, M. L., Willman, C. L., Carroll, W. L. (2008). Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study on Behalf of the Dutch Childhood Oncology Group and the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia. JCO 26: 4376-4384 [Abstract] [Full Text]  
• Goetz, M. P., Suman, V. J., Couch, F. J., Ames, M. M., Rae, J. M., Erlander, M. G., Ma, X.-J., Sgroi, D. C., Reynolds, C. A., Lingle, W. L., Weinshilboum, R. M., Flockhart, D. A., Desta, Z., Perez, E. A., Ingle, J. N. (2008). Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance. Clin. Cancer Res. 14: 5864-5868 [Abstract] [Full Text]  
• Castro, E., de Alava, E. (2008). The risk of taking the part by the whole. Ann Oncol 0: mdn598v1-mdn598 [Full Text]  
• Creighton, C. J., Casa, A., Lazard, Z., Huang, S., Tsimelzon, A., Hilsenbeck, S. G., Osborne, C. K., Lee, A. V. (2008). Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis. JCO 26: 4078-4085 [Abstract] [Full Text]  
• Eszlinger, M., Krohn, K., Hauptmann, S., Dralle, H., Giordano, T. J., Paschke, R. (2008). Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors. J. Clin. Endocrinol. Metab. 93: 3286-3294 [Abstract] [Full Text]  
• John, T., Black, M. A., Toro, T. T., Leader, D., Gedye, C. A., Davis, I. D., Guilford, P. J., Cebon, J. S. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clin. Cancer Res. 14: 5173-5180 [Abstract] [Full Text]  
• Landemaine, T., Jackson, A., Bellahcene, A., Rucci, N., Sin, S., Abad, B. M., Sierra, A., Boudinet, A., Guinebretiere, J.-M., Ricevuto, E., Nogues, C., Briffod, M., Bieche, I., Cherel, P., Garcia, T., Castronovo, V., Teti, A., Lidereau, R., Driouch, K. (2008). A Six-Gene Signature Predicting Breast Cancer Lung Metastasis. Cancer Res. 68: 6092-6099 [Abstract] [Full Text]  
• Somlo, G., Chu, P., Frankel, P., Ye, W., Groshen, S., Doroshow, J. H., Danenberg, K., Danenberg, P. (2008). Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol 0: mdn402v1-mdn402 [Abstract] [Full Text]  
• Turner, N. C, Jones, A. L (2008). Management of breast cancer--Part II. BMJ 337: a540-a540 [Full Text]  
• Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., Wang, Y., Marcom, P. K., Marks, J. R., Febbo, P. G., Nevins, J. R., Potti, A., Blackwell, K. L. (2008). Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression. JCO 26: 3324-3330 [Abstract] [Full Text]  
• Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kolbl, H., Gehrmann, M. (2008). The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. Cancer Res. 68: 5405-5413 [Abstract] [Full Text]  
• Del Mastro, L. (2008). The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. Ann Oncol 19: 1213-1215 [Full Text]  
• Weinberg, R. A. (2008). Mechanisms of malignant progression. Carcinogenesis 29: 1092-1095 [Full Text]  
• Rakha, E. A., Reis-Filho, J. S., Ellis, I. O. (2008). Basal-Like Breast Cancer: A Critical Review. JCO 26: 2568-2581 [Abstract] [Full Text]  
• Willis, A. L., Tran, N. L., Chatigny, J. M., Charlton, N., Vu, H., Brown, S. A.N., Black, M. A., McDonough, W. S., Fortin, S. P., Niska, J. R., Winkles, J. A., Cunliffe, H. E. (2008). The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity. Mol Cancer Res 6: 725-734 [Abstract] [Full Text]  
• Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., Sgroi, D. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin. Cancer Res. 14: 2601-2608 [Abstract] [Full Text]  
• Korsching, E, Jeffrey, S S, Meinerz, W, Decker, T, Boecker, W, Buerger, H (2008). Basal carcinoma of the breast revisited: an old entity with new interpretations. J. Clin. Pathol. 61: 553-560 [Abstract] [Full Text]  
• Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2008). Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 13: 477-493 [Abstract] [Full Text]  
• Bullinger, L., Dohner, K., Kranz, R., Stirner, C., Frohling, S., Scholl, C., Kim, Y. H., Schlenk, R. F., Tibshirani, R., Dohner, H., Pollack, J. R. (2008). An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 111: 4490-4495 [Abstract] [Full Text]  
• Acharya, C. R., Hsu, D. S., Anders, C. K., Anguiano, A., Salter, K. H., Walters, K. S., Redman, R. C., Tuchman, S. A., Moylan, C. A., Mukherjee, S., Barry, W. T., Dressman, H. K., Ginsburg, G. S., Marcom, K. P., Garman, K. S., Lyman, G. H., Nevins, J. R., Potti, A. (2008). Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA 299: 1574-1587 [Abstract] [Full Text]  
• Garcia, I., Tabak, L. A. (2008). Beyond the "Omics": Translating Science Into Improved Health. Journal of the American Dental Association 139: 392-395 [Full Text]  
• Shen, Q., Rahn, J. J., Zhang, J., Gunasekera, N., Sun, X., Shaw, A. R.E., Hendzel, M. J., Hoffman, P., Bernier, A., Hugh, J. C. (2008). MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1. Mol Cancer Res 6: 555-567 [Abstract] [Full Text]  
• Pusztai, L. (2008). Current Status of Prognostic Profiling in Breast Cancer. The Oncologist 13: 350-360 [Abstract] [Full Text]  
• Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Grogan, G. M., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., Darbon, J.-M. (2008). A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clin. Cancer Res. 14: 1744-1752 [Abstract] [Full Text]  
• Bear, H. D. (2008). Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them?. JCO 26: 1195-1197 [Full Text]  
• Marchionni, L., Wilson, R. F., Wolff, A. C., Marinopoulos, S., Parmigiani, G., Bass, E. B., Goodman, S. N. (2008). Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. ANN INTERN MED 148: 358-369 [Abstract] [Full Text]  
• Cheang, M. C.U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., Nielsen, T. O. (2008). Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clin. Cancer Res. 14: 1368-1376 [Abstract] [Full Text]  
• Sparano, J. A., Paik, S. (2008). Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. JCO 26: 721-728 [Abstract] [Full Text]  
• Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., Jeffrey, S. S. (2008). Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression. Radiology 246: 367-375 [Abstract] [Full Text]  
• Rakha, E., Ellis, I., Reis-Filho, J. (2008). Are Triple-Negative and Basal-Like Breast Cancer Synonymous?. Clin. Cancer Res. 14: 618-618 [Full Text]  
• Dobbe, E., Gurney, K., Kiekow, S., Lafferty, J. S., Kolesar, J. M. (2008). Gene-expression assays: New tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm 65: 23-28 [Abstract] [Full Text]  
• Dumur, C. I., Lyons-Weiler, M., Sciulli, C., Garrett, C. T., Schrijver, I., Holley, T. K., Rodriguez-Paris, J., Pollack, J. R., Zehnder, J. L., Price, M., Hagenkord, J. M., Rigl, C. T., Buturovic, L. J., Anderson, G. G., Monzon, F. A. (2008). Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated Cancers. J. Mol. Diagn. 10: 67-77 [Abstract] [Full Text]  
• Dobbin, K. K., Zhao, Y., Simon, R. M. (2008). How Large a Training Set is Needed to Develop a Classifier for Microarray Data?. Clin. Cancer Res. 14: 108-114 [Abstract] [Full Text]  
• Gupta, G. P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Todorova-Manova, K., Gerald, W. L., Brogi, E., Benezra, R., Massague, J. (2007). ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. USA 104: 19506-19511 [Abstract] [Full Text]  
• Lusa, L., McShane, L. M., Reid, J. F., De Cecco, L., Ambrogi, F., Biganzoli, E., Gariboldi, M., Pierotti, M. A. (2007). Challenges in Projecting Clustering Results Across Gene Expression Profiling Datasets. JNCI J Natl Cancer Inst 99: 1715-1723 [Abstract] [Full Text]  
• Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E., Chlouverakis, G., Sotiriou, C., Georgoulias, V., Mavroudis, D. (2007). Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. JCO 25: 5194-5202 [Abstract] [Full Text]  
• Alexe, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesirov, J. P., DeLisi, C., Harris, L., Barnard, N., Martel, M., Levine, A. J., Ganesan, S., Bhanot, G. (2007). High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. Cancer Res. 67: 10669-10676 [Abstract] [Full Text]  
• Thomassen, M., Tan, Q., Eiriksdottir, F., Bak, M., Cold, S., Kruse, T. A. (2007). Comparison of Gene Sets for Expression Profiling: Prediction of Metastasis from Low-Malignant Breast Cancer. Clin. Cancer Res. 13: 5355-5360 [Abstract] [Full Text]  
• Ioannidis, J. P A (2007). Genetic and molecular epidemiology. J. Epidemiol. Community Health 61: 757-758 [Abstract] [Full Text]  
• Badve, S., Turbin, D., Thorat, M. A., Morimiya, A., Nielsen, T. O., Perou, C. M., Dunn, S., Huntsman, D. G., Nakshatri, H. (2007). FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival. Clin. Cancer Res. 13: 4415-4421 [Abstract] [Full Text]  
• Pollack, J. R. (2007). A Perspective on DNA Microarrays in Pathology Research and Practice. Am. J. Pathol. 171: 375-385 [Abstract] [Full Text]  
• Dunlap, S. M., Celestino, J., Wang, H., Jiang, R., Holland, E. C., Fuller, G. N., Zhang, W. (2007). Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc. Natl. Acad. Sci. USA 104: 11736-11741 [Abstract] [Full Text]  
• Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. -J., Panel Members, (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144 [Abstract] [Full Text]  
• Mullins, M., Perreard, L., Quackenbush, J. F., Gauthier, N., Bayer, S., Ellis, M., Parker, J., Perou, C. M., Szabo, A., Bernard, P. S. (2007). Agreement in Breast Cancer Classification between Microarray and Quantitative Reverse Transcription PCR from Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Tissues. Clin. Chem. 53: 1273-1279 [Abstract] [Full Text]  
• Dimitrov, N. V., Colucci, P., Nagpal, S. (2007). Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer. The Oncologist 12: 798-807 [Abstract] [Full Text]  
• Dyrskjot, L., Zieger, K., Real, F. X., Malats, N., Carrato, A., Hurst, C., Kotwal, S., Knowles, M., Malmstrom, P.-U., de la Torre, M., Wester, K., Allory, Y., Vordos, D., Caillault, A., Radvanyi, F., Hein, A.-M. K., Jensen, J. L., Jensen, K. M.E., Marcussen, N., Orntoft, T. F. (2007). Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. Clin. Cancer Res. 13: 3545-3551 [Abstract] [Full Text]  
• Larsen, J. E., Pavey, S. J., Passmore, L. H., Bowman, R. V., Hayward, N. K., Fong, K. M. (2007). Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma. Clin. Cancer Res. 13: 2946-2954 [Abstract] [Full Text]  
• Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., Veronesi, A., Muss, H. (2007). Breast Cancer in the Elderly. JCO 25: 1882-1890 [Abstract] [Full Text]  
• Bertucci, F., Cervera, N., Birnbaum, D., Wennmalm, K., Miller, L. D., Bergh, J., Woodward, W. A., Lucci, A., Cristofanilli, M., the Advanced Research Center for Micrometastatic D, , Clarke, M. F., Liu, R., Wang, X. (2007). A Gene Signature in Breast Cancer. NEJM 356: 1887-1888 [Full Text]  
• Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmstrom, P., Memeo, L., Isola, J., Bendahl, P.-O., Rosen, N., Hibshoosh, H., Ringner, M., Borg, A., Parsons, R. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 104: 7564-7569 [Abstract] [Full Text]  
• Minn, A. J., Gupta, G. P., Padua, D., Bos, P., Nguyen, D. X., Nuyten, D., Kreike, B., Zhang, Y., Wang, Y., Ishwaran, H., Foekens, J. A., van de Vijver, M., Massague, J. (2007). Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. USA 104: 6740-6745 [Abstract] [Full Text]  
• Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., Perou, C. M. (2007). The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin. Cancer Res. 13: 2329-2334 [Abstract] [Full Text]  
• Shak, S., Palmer, G., Baker, J. (2007). Re: Breast Cancer Gene Microarrays Pass Muster. JNCI J Natl Cancer Inst 99: 572-573 [Full Text]  
• Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., Klijn, J. G.M., Larsimont, D., Buyse, M., Bontempi, G., Delorenzi, M., Piccart, M. J., Sotiriou, C. (2007). Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. JCO 25: 1239-1246 [Abstract] [Full Text]  
• Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., Clark, E. (2007). Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection. Cancer Res. 67: 2226-2238 [Abstract] [Full Text]  
• Ioannidis, J. P. A. (2007). Is Molecular Profiling Ready for Use in Clinical Decision Making?. The Oncologist 12: 301-311 [Abstract] [Full Text]  
• Jansen, M. P.H.M., Sieuwerts, A. M., Look, M. P., Ritstier, K., Meijer-van Gelder, M. E., van Staveren, I. L., Klijn, J. G.M., Foekens, J. A., Berns, E. M.J.J. (2007). HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. JCO 25: 662-668 [Abstract] [Full Text]  
• Goetz, M. P., Ingle, J. N., Couch, F. J., Fan, C., van't Veer, L. J., Perou, C. M. (2007). Gene-Expression-Based Predictors for Breast Cancer. NEJM 356: 752-753 [Full Text]  
• Lillie, S. E., Brewer, N. T., O'Neill, S. C., Morrill, E. F., Dees, E. C., Carey, L. A., Rimer, B. K. (2007). Retention and Use of Breast Cancer Recurrence Risk Information from Genomic Tests: The Role of Health Literacy. Cancer Epidemiol. Biomarkers Prev. 16: 249-255 [Abstract] [Full Text]  
• Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K., Clarke, M. F. (2007). The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells. NEJM 356: 217-226 [Abstract] [Full Text]  
• Massague, J. (2007). Sorting Out Breast-Cancer Gene Signatures. NEJM 356: 294-297 [Full Text]  
• Sun, Z., Yang, P., Singh, T., Dhindsa, J., Larsen, J. E., Fong, K. M., Hayward, N. K., Potti, A., Harpole, D. H. Jr., Nevins, J. R. (2007). Refining Prognosis in Non-Small-Cell Lung Cancer. NEJM 356: 189-191 [Full Text]  
• Herbst, R. S., Lippman, S. M. (2007). Molecular Signatures of Lung Cancer -- Toward Personalized Therapy. NEJM 356: 76-78 [Full Text]  
• Pusztai, L. (2006). Chips to Bedside: Incorporation of Microarray Data into Clinical Practice. Clin. Cancer Res. 12: 7209-7214 [Full Text]  
• O'Shaughnessy, J. A. (2006). Molecular Signatures Predict Outcomes of Breast Cancer. NEJM 355: 615-617 [Full Text]